Clinical patterns in asthma based on proximal and distal airway nitric oxide categories by Puckett, James L et al.
Puckett et al. Respiratory Research 2010, 11:47
http://respiratory-research.com/content/11/1/47
Open Access RESEARCH
BioMed  Central
© 2010 Puckett et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research Clinical patterns in asthma based on proximal and 
distal airway nitric oxide categories
James L Puckett†1, Richard WE Taylor†1, Szu-Yun Leu†2, Olga L Guijon†3, Anna S Aledia†1,4, Stanley P Galant†3 and 
Steven C George*†1,5
Abstract
Background: The exhaled nitric oxide (eNO) signal is a marker of inflammation, and can be partitioned into proximal 
[J'awNO (nl/s), maximum airway flux] and distal contributions [CANO (ppb), distal airway/alveolar NO concentration]. We 
hypothesized that J'awNO and CANO are selectively elevated in asthmatics, permitting identification of four 
inflammatory categories with distinct clinical features.
Methods: In 200 consecutive children with asthma, and 21 non-asthmatic, non-atopic controls, we measured baseline 
spirometry, bronchodilator response, asthma control and morbidity, atopic status, use of inhaled corticosteroids, and 
eNO at multiple flows (50, 100, and 200 ml/s) in a cross-sectional study design. A trumpet-shaped axial diffusion model 
of NO exchange was used to characterize J'awNO and CANO.
Results: J'awNO was not correlated with CANO, and thus asthmatic subjects were grouped into four eNO categories 
based on upper limit thresholds of non-asthmatics for J'awNO (≥ 1.5 nl/s) and CANO (≥ 2.3 ppb): Type I (normal J'awNO 
and CANO), Type II (elevated J'awNO and normal CANO), Type III (elevated J'awNO and CANO) and Type IV (normal J'awNO 
and elevated CANO). The rate of inhaled corticosteroid use (lowest in Type III) and atopy (highest in Type II) varied 
significantly amongst the categories influencing J'awNO, but was not related to CANO, asthma control or morbidity. All 
categories demonstrated normal to near-normal baseline spirometry; however, only eNO categories with increased 
CANO (III and IV) had significantly worse asthma control and morbidity when compared to categories I and II.
Conclusions: J'awNO and CANO reveal inflammatory categories in children with asthma that have distinct clinical 
features including sensitivity to inhaled corticosteroids and atopy. Only categories with increase CANO were related to 
poor asthma control and morbidity independent of baseline spirometry, bronchodilator response, atopic status, or use 
of inhaled corticosteroids.
Background
Asthma is a complex disease characterized by inflamma-
tion throughout the respiratory tract from the large air-
ways to the alveoli [1-3]. Moreover, there is mounting
evidence that asthma control is correlated with the extent
of inflammation, such that symptoms are worse when the
inflammation reaches the more peripheral lung compart-
ments [2-6]. One of the great challenges in asthma
research is to develop minimally invasive approaches,
particularly in children, that could assess the site and
extent of inflammation. Such tools could enhance our
understanding of the mechanisms that characterize
asthma, and prove useful in choosing appropriate thera-
pies [7].
There is mounting data that analysis of exhaled nitric
oxide (eNO) could serve as a non-invasive indicator of
the extent and site of inflammation in asthma. eNO is a
flow dependent signal [8,9], and current guidelines [10]
stipulate an exhalation flow of 50 ml/s (FENO,50). FENO,50 is
purported to be a marker of airway inflammation, since it
is elevated in steroid naïve asthmatics [11], reduced upon
administration of anti-inflammatory medications [12],
and is correlated with biological [13-15] and physiological
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[16-18] markers of airway inflammation. However, some
patients may fulfill the criteria for the diagnosis of
asthma, and yet FENO,50  levels will be normal [19].
Numerous longitudinal studies have investigated the use
of FENO,50 as a tool in the clinical management of asthma
[20-27]. The results of these studies have been mixed, as
four of the studies demonstrated that FENO,50 was of lim-
ited use in managing asthmatic symptoms and corticos-
teroid dose [20,23,24,26]; however, methodological issues
in the design of these studies have been raised [28].
Therefore, despite the undeniable link between NO and
inflammation, the promise of FENO,50  as a surrogate
marker of airway inflammation has yet to be fulfilled, and
an alternate approach may be indicated [29].
eNO can be partitioned into proximal airway [J'awNO
(nl/s), maximum airway flux, generations 1-16] and distal
airway/alveolar contributions [CANO (ppb), alveolar NO
concentration, generations 17-23] (Fig. 1A). Increased
J'awNO with normal CANO has been reported in adults
[30] and children [6] with mild asthma, whereas CANO
h a s  b e e n  r e p o r t e d  t o  b e  i n c r e a s e d  i n  a s t h m a t i c s  w i t h
poor control [5], enhanced symptoms [31], more severe
disease [32], and be a predictor of asthma exacerbation in
adults [33]. These findings suggest that J'awNO and CANO
may be selectively increased and thus independently
characterize proximal and distal lung inflammation (Fig.
1B). Hence, we hypothesized that J'awNO and CANO can
be selectively elevated in children with asthma, creating
four eNO categories, characterized by distinct clinical
features.
Methods
Study participants
Two hundred pediatric patients with signs and symptoms
of asthma within the past three months who presented to
the Children's Hospital of Orange County (CHOC)
Breathmobile, a mobile asthma clinic staffed with asthma
specialists, for an asthma evaluation participated in the
cross-sectional study. Criteria for the diagnosis of asthma
included a previous history of recurrent coughing,
wheezing, shortness of breath (at rest or following exer-
cise), and symptomatic improvement following short act-
ing bronchodilator [1]. Patients were included and
considered steroid naïve if they reported no use of
inhaled corticosteroid (ICS) in the past 8 weeks, or con-
sidered steroid treated if they have reported compliance
with prescribed ICS therapy based on NAEPP (National
Asthma Education and Prevention Program) guidelines
over the previous 8 weeks. Patients were excluded from
the study if they had any other heart or lung disease, any
smoking within the past five years, or they were ICS
treated for less than 8 weeks. Short and long acting β2
agonists were withheld for 12 hours prior to the study.
Additionally, twenty-one non-asthmatic non-atopic chil-
dren were enrolled in the study. Each subject and their
guardian completed the informed consent documents
which had been approved by the University of California,
Irvine and CHOC Institutional Review Boards.
Measurements
Asthma symptoms were quantified using the validated
Asthma Control Test (ACT) for children (age 6 - 11 years)
[34] and adults (age 12 - 17 years) [35]. Retrospective data
on asthma risk factors were collected by the physician.
These included severe attacks (exacerbation requiring
increased use of albuterol and short-term oral corticos-
teroids when available), emergency department visits, or
hospitalizations within the preceding 8 weeks. Skin prick
tests for common allergens (cat, dog, feathers, cockroach,
dust mites, mold, weeds, trees and grasses) were per-
formed, and the participant was considered atopic if pos-
itive to at least one antigen.
The eNO measurements at multiple flows (50 ml/s, 100
ml/s and 200 ml/s; NIOX Flex, Aerocrine Ltd, Stockholm,
Sweden) were performed prior to the pre-bronchodilator
spirometric maneuver. eNO measurements at all three
Figure 1 Schematic of two-compartment model and four eNO 
categories. A) During exhalation of nitric oxide (eNO), a steady state 
mean distal airway/alveolar concentration (CANO, ppb) enters the con-
ducting airway compartment (net transfer is convection minus diffu-
sion) where upon additional NO is transferred from the proximal 
airway walls (J'awNO, nl/s). CANO represents the respiratory region of the 
lungs (Weibel generations 17-23). J'awNO represents the larger con-
ducting airway region of the lungs (Weibel generations 1-16), and con-
siders the increasing surface area per unit volume of the airway tree 
(i.e., trumpet shape). [T: trachea; TB: terminal bronchiole; RB: respiratory 
bronchiole; AS: alveolar sac]. B) J'awNO and CANO can be selectively ele-
vated (thick gray shading) and may independently characterize proxi-
mal and distal lung inflammation, creating four eNO categories: Type I, 
normal J'awNO and normal CANO; Type II, elevated J'awNO and normal 
CANO; Type III, elevated J'awNO and elevated CANO; and Type IV, normal 
J'awNO and elevated CANO.
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flows were performed in triplicate in accordance with
ATS guidelines [10], and the order of the nine maneuvers
randomized. The physicians did not have access to eNO
data at any time; hence clinical management was based
solely on history and spirometry.
Standard spirometry was performed (WinDx Spirome-
ter, Creative Biomedics International, CA) in accordance
with ATS criteria [36]. To determine the bronchodilator
response (BDR), albuterol (180 mcg; 2 puff with spacer)
was administered and spirometry was repeated 10 min-
utes later. The BDR was calculated as the percent change
in FEV1 following administration of albuterol.
Calculation of J'awNO and CANO
The average eNO concentration at each flow was calcu-
lated following current ATS guidelines [10]. Utilizing a
trumpet-shaped model of NO exchange that accounts for
axial diffusion [37], we applied a linear least squares anal-
ysis to a plot of the average NO elimination rate (product
of average exhaled NO and average flow) versus the aver-
age exhalation flow to estimate J'awNO and CANO [38].
Statistical analysis
Spearman rank-order correlation was first evaluated
among eNO measurements to evaluate the relationships
between FENO, J'awNO and CANO, and the asthmatic sub-
jects were further categorized into four categories based
on J'awNO and CANO. Clinical features were compared
among the four categories and with the non-asthmatic
controls using the Kruskal-Wallis test and the Mantel-
Haenszel chi-square test. For variables with significant
differences among the groups, paired comparisons were
applied with Bonferroni's multiple comparison adjust-
ment. Data are reported using median and range (mini-
mum-maximum), or number of subjects and proportion.
Significance level was set at 0.05, and analysis was per-
formed using SAS 9 (Cary, NC).
Results
In both asthmatic and non-asthmatic populations, 95% of
the participants reported an ethnicity of Hispanic. All of
the enrolled subjects were able to perform the exhaled
NO and spirometric maneuvers. However, among the
asthmatic subjects, one was excluded due to missing
spirometric data, and twenty were excluded from the
analysis since their eNO at multiple exhalation flows did
not fit the linear model of NO exchange; this was due to a
negative estimated CANO (i.e., non-physiologic interpre-
tation). General features of the entire asthma population
are summarized in the first column of Table 1. Our group
of asthmatic children was generally mild and well-con-
trolled (median ACT score of 21) with normal baseline
spirometry (median FEV1/FVC = 87.0).
FENO,50, J'awNO, and CANO in non-asthmatic control group
In the non-asthmatic non-atopic children, the median
and range of FENO,50, J'awNO and CANO were found to be
8.5 (2.2-15.3), 0.67 (0.13 - 1.44) nl/s, and 1.47 (0.1 - 2.23)
ppb, respectively (Table 1). Based on this distribution,
and rounding up the maximum value to two significant
digits produces a conservative estimate of a threshold for
elevated FENO,50, proximal airway NO, and distal airway/
alveolar NO: FENO,50 ≥ 16 ppb, J'awNO ≥ 1.5 nl/s and CANO
≥ 2.3 ppb. The results for J'awNO and CANO are similar to
the findings of other reports using the two compartment
model [39] to partition exhaled NO in non-asthmatic
children when axial diffusion is considered [5,40].
Correlations among FENO and regional nitric oxide 
parameters
In the asthmatic subjects, J'awNO is strongly correlated
with FENO,50 (r = 0.99), FENO,100 (r = 0.93) and FENO,200 (r =
0.95). CANO is not correlated with FENO,50 (r = 0.09) or
FENO,100 (r = 0.11). At the highest flow of 200 ml/s, the
c o n t r i b u t i o n  o f  t h e  p r o x i m a l  a i r w a y s  i s  r e d u c e d ,  b u t
CANO  is only very weakly correlated (r = 0.23) with
FENO,200.
Exhaled nitric oxide (eNO) categories
CANO and J'awNO are not correlated (r = -0.002) indicat-
ing that they provide independent information. Hence,
asthmatic subjects were classified into four eNO catego-
ries (Fig. 2) based on the upper limit of non-asthmatic
thresholds for J'awNO (≥ 1.5 nl/s) and CANO (≥ 2.3 ppb):
Type I: J'awNO and CANO not elevated; n = 67, (37%)
Type II: elevated J'awNO; n = 66, (37%)
Type III: elevated J'awNO and elevated CANO; n = 27,
(15%)
Type IV: elevated CANO; n = 19, (11%)
There were no gender or age differences amongst the
four eNO categories and the non-asthmatic controls
(Table 1). The proportion of atopic subjects was signifi-
cantly different between the groups (p = 0.0001, Table 1),
where Type II had significantly higher rates compared to
Type I and Type IV.
Based on patient history, inhaled corticosteroid (ICS)
naïve was defined as no oral or ICS within the last 8
weeks and ICS treated was defined as prescribed ICS
treatment for at least 8 weeks. Significant differences (p <
0.0001, Table 1) existed between the eNO categories with
respect to ICS use. The proportion of subjects who were
ICS treated was significantly less in Type III when com-
pared to the other eNO categories and was significantly
less in Type II compared to Type I.
As defined above, J'awNO was elevated in Type II [3.0
(1.6-17.0) nl/s] and Type III [3.5 (1.5-13.7) nl/s] but not inP
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Table 1: Clinical data and risk factors for the exhaled nitric oxide categories
All
asthmatics
(n = 179)
Non-asthmatic
(n = 21)
Type I
Normal Nitric 
Oxide
(n = 67)
Type II
Proximal Airway 
Predominant
(n = 66)
Type III
Proximal and Distal 
Airway Predominant
(n = 27)
Type IV
Distal Airway 
Predominant
(n = 19)
Overall test
p-value#
Paired compar-
ison result$
DEMOGRAPHICS
Age 10
(6-17)
10
(6-17)
10
(6-17)
11
(6-17)
11
(6-16)
11
(6-17)
0.13 -----
Gender
Male
117
(65%)
12
(57%)
48
(72%)
44
(67%)
16
(59%)
9
(47%)
0.30 -----
Atopy 143
(80%)
0
(0%)
44
(66%)
62
(94%)
23
(89%)
12
(63%)
0.0001 II>I, IV
ICS
treatment
110
(61%)
----- 53
(79%)
37
(56%)
5
(18%)
15
(79%)
<0.0001 III<I, II, IV
II<I
EXHALED NITRIC OXIDE
FENO,50 19.6
(3.7-186)
8.5
(2.2-15.3)
9.4
(3.7-18.4)
33.4
(17.7-186)
49.9
(22.3-159)
8.5
(4.6-16.9)
0.0001 II, III>NC, I, IV
III>II
J'awNO (nl/s) 1.6
(0.1-17)
0.7
(0.1-1.4)
0.7
(0.1-1.5)
3.0
(1.6-17)
3.5
(1.5-13.7)
0.5
(0.1-1.3)
0.0001 II, III>NC, I, IV
CANO (ppb) 1.3
(0.1-13.4)
1.5
(0.1-2.2)
1.0
(0.006-2.3)
0.8
(0.02-2.2)
3.8
(2.4-13.4)
3.1
(2.3-5.1)
0.0001 III, IV>NC, I, II
III>IV
CONTROL and MORBIDITY
FEV1/FVC 87.0
(70.4-102.1)
89.6
(84.5-102.1)
89.4
(71.7-100)
85.5
(70.4-101)
83.3
(72-100.1)
87.8
(80.7-100.7)
0.0016 III<I, NC
FEV1 (%) 106
(67.1-149)
106
(92.6-118)
108
(75.1-149)
105
(67.1-149)
106
(76.2-132)
103
(77.9-127)
0.68 -----
BDR 6.3
(0-35.5)
[n = 167]
5.3
(0.6-6.6)
[n = 13]
4.1
(0-13.8)
[n = 63]
7.0
(0-27.4)
[n = 60]
10.1
(0.7-35.5)
[n = 26]
5.0
(0.7-10.6)
[n = 18]
<0.0001 II>I
III>NC, I, IV
ACT 21
(10-27)
----- 23
(17-27)
22
(17-26)
17
(10-23)
17
(10-24)
<0.0001 III, IV<I, II
Morbidity* 26
(15%)
----- 8
(12%)
3
(4.5%)
9
(33%)
6
(32%)
<0.0001 III, IV>II
Data is presented as median (minimum-maximum) or number of subjects (proportion). NC, non-asthmatic control; ICS, inhaled corticosteroid; ACT, Asthma Control Test; BDR, bronchodilator 
response;
* Number of subjects with at least one event in the past 8 weeks including visits to the emergency department, severe attacks, and hospitalizations.
#Mantel-Haenszel chi-square test for Gender, Atopy, ICS treatment and Morbidity; and Kruskal-Wallis test for all other variables. Comparisons made between non-asthmatic control and Type I-IV 
categories
$Bonferroni's multiple comparison adjustment was applied for paired comparison.Puckett et al. Respiratory Research 2010, 11:47
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non-asthmatic controls [0.7 (0.1-1.4) nl/s], Type I [0.7
(0.1-1.5) nl/s] and Type IV [0.5 (0.1-1.3) nl/s]. There was
no difference in J'awNO between Type II and Type III.
Details are summarized in Table 1.
Also, by design, CANO was elevated in Type III [3.8 (2.4-
13.4) ppb] and Type IV [3.1 (2.3-5.1) ppb] but not in non-
asthmatic controls [1.5 (0.1-2.2) ppb], Type I [1.0 (0.006-
2.3) ppb] and Type II [0.8 (0.02-2.2) ppb] (Table 1). Fur-
thermore, CANO was found to be significantly (p = 0.02)
greater in Type III when compared to Type IV.
Since FENO,50  was strongly correlated with J'awNO,
FENO,50 was significantly elevated in Type II [33.4 (17.7-
186.2) ppb] and Type III [49.9 (22.3-158.9) ppb] when
compared to non-asthmatic controls [8.5 (2.2-15.3) ppb],
Type I [9.4 (3.7-18.4) ppb] and Type IV [8.5 (4.6-16.9)
ppb] (Table 1). However, it was also found that FENO,50
was significantly higher in Type III than Type II.
Clinical patterns of eNO categories
There were significant differences in FEV1/FVC ratio (p =
0.0016), where Type III [83.3 (72-100.1)] was lower than
non-asthmatic controls [89.6 (84.5-102.1)] and Type I
[89.4 (71.7-100)]. However, the median FEV1/FVC for
Type III was within normal limits based on NHLBI/
NAEPP guidelines [1]. With regards to FEV1/FVC < 80%,
there were approximately 4%, 18%, 22% and 0% for Types
I to IV, respectively. There were no significant differences
in FEV1 (% predicted) amongst the four eNO categories
and the non-asthmatic controls (Table 1).
The BDR was performed in 180 subjects and was found
to be significantly different (p < 0.0001, Table 1) amongst
the five groups. The BDR in Type III was found to be sig-
nificantly greater than non-asthmatic controls, Type I,
and Type IV. Furthermore, the BDR in Type II was signif-
icantly greater than Type I.
The ACT score was significantly different (p < 0.0001,
Table 1) amongst the eNO categories. The ACT scores in
Type III and Type IV were significantly lower compared
to Type I and Type II. Over 80% of Type I and Type II had
an ACT score > 19, indicative of good asthma control;
while 78% of Type III and 90% of Type IV had and ACT
score ≤ 19, indicative of poor asthma control.
The retrospective asthma risk factors (severe attacks,
emergency department visits, and hospitalizations) were
defined as any event during the last eight weeks (Table 1).
There were significant differences amongst the eNO cate-
gories in the proportion of children with at least one
asthma morbidity event (p < 0.0001, Table 1). Multiple
comparison adjustment demonstrated that the frequency
of morbidity events was significantly greater in Type III
and Type IV when compared to Type II.
Discussion
Our study has demonstrated that proximal airway
(J'awNO) and distal airway/alveolar NO (CANO) are not
correlated in children with generally mild well-controlled
asthma, thus allowing identification of four distinct eNO
categories: Type I (normal nitric oxide), Type II (proximal
airway predominant), Type III (proximal and distal air-
way predominant) and Type IV (distal airway predomi-
nant). Our main finding is that eNO categories with
increased CANO (i.e., Type III and Type IV) have much
worse asthma control and morbidity (Table 1), despite
different rates of ICS treatment, atopy, baseline spirome-
try, and BDR. Together, these findings support the pres-
ence of distinct inflammatory categories based on
regional eNO, and suggest that distal NO (CANO) may be
a more clinically sensitive, objective measure of asthma
control compared to spirometry and proximal NO
(FENO,50, J'awNO).
Inflammatory categories in asthma
Traditionally, asthma has been grouped into two catego-
ries on the basis of etiology [41]: intrinsic and extrinsic.
More recently, management guidelines have stratified
asthma on the basis of severity [1]. However, the severity
classification scheme does not consider the degree of air-
way inflammation, a factor which could improve clinical
Figure 2 Exhaled nitric oxide (eNO) categories. Scatter plot be-
tween maximum proximal airway nitric oxide flux (J'awNO) and distal 
airway/alveolar nitric oxide concentration (CANO). When axial diffusion 
is considered, there is no correlation (Spearman rank, r = -0.002) be-
tween J'awNO and CANO. Asthmatic eNO categories based on thresh-
olds for non-asthmatics J'awNO(≤ 1.5 nl/s) and CANO (≤ 2.3 ppb): Type I 
(white triangle), normal J'awNO and normal CANO; Type II (white dia-
mond), elevated J'awNO and normal CANO; Type III (white circle), elevat-
ed J'awNO and elevated CANO; and Type IV (white square), normal 
J'awNO and elevated CANO.
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management [42,43]. There are only a few reports which
utilize inflammatory patterns to characterize adult
asthma [44-46] and none to the best of our knowledge,
describe inflammatory categories in pediatric asthma.
The idea of stratifying asthma based on inflammatory
patterns was first presented by Wenzel et al. in 1999 [44];
severe asthmatics were divided into two subtypes based
on the presence or absence of eosinophils in the bron-
chial biopsy specimen. In a 2006 study by Simpson et al.
[45], the asthmatics were segregated into four inflamma-
tory subtypes using induced sputum eosinophil and neu-
trophils counts. More recently, a 2009 study by Nadif et
al. [46] demonstrated that blood eosinophil and neutro-
phil counts can be used to characterize adult asthma.
However, these methods are more invasive in nature,
more challenging to perform in children, and may not be
ideally suited for the serial monitoring of asthmatic sub-
jects. The current data suggest a relatively simple
approach for non-invasively gauging information about
the location and extent of inflammation in the asthmatic
lung.
A general summary of the eNO categories is presented
in Table 2. Well-controlled asthmatics generally appear in
Type I and Type II categories. The common features
between these categories are the absence of distal airway/
alveolar inflammation (low CANO) and normal baseline
spirometry, despite differences in proximal NO (FENO,50
and J'awNO), ICS treatment, atopy, and BDR. In contrast,
poorly controlled asthmatics tend to fall into Type III and
Type IV categories. The common features between these
categories are the presence of distal airway/alveolar
inflammation (high CANO), despite differences in proxi-
mal NO (FENO,50 and J'awNO), ICS treatment, and BDR.
Thus, distal inflammation, as indicated by an elevated
CANO, appears to be the most robust predictor of asthma
control in our group of relatively mild asthmatic children
relative to traditional indices such as baseline spirometry
and ICS therapy.
Proximal versus distal airway inflammation
Our observation that J'awNO is strongly related to FENO,50
indicates that an exhalation flow of 50 ml/s is low enough
such that FENO,50 is dominated by the proximal airway
contribution, and partitioning the exhaled NO signal to
estimate J'awNO  provides no additional information.
Therefore, to characterize the inflammatory status of the
proximal lung FENO,50 is sufficient. However, even though
the distal airway/alveolar concentration is a greater frac-
tion of FENO at higher flows, it remains very small, and
FENO,200 is only very weakly correlated with CANO; hence,
the exhaled NO signal must be partitioned using a math-
ematical model to estimate the much smaller concentra-
tion of CANO. Our observation that J'awNO and CANO are
not correlated indicates they provide independent infor-
mation regarding region specific NO. Of note is the con-
founding role of axial diffusion of NO which has been
demonstrated in both healthy adults [37,47-49] and those
with stable asthma)[50], but not in active asthma; if axial
diffusion of NO is not considered in our data set, then a
strong positive relationship (r = 0.71) is observed
between J'awNO and CANO. In other words, a significant
proximal airway source can contaminate the distal air-
way/alveolar region via axial (or "back") diffusion leading
to an artificial elevation in CANO and an erroneous posi-
tive correlation.
Proximal airway NO (FENO,50 and J'awNO) has not been
consistently associated with asthma control or a predic-
tor of exacerbation [20-23]. One possibility for these find-
ings is the confounding influences of ICS therapy and
atopy, both of which strongly impact proximal airway NO
[5,12,51-53]. For example, Paraskakis et. al [5] has dem-
onstrated that FENO,50 is no different between asthmatic
and atopic non-asthmatic children. In our categories,
FENO,50  (and J'awNO) progressively increased between
Types I, II, and III (9.4, 33.4, 49.9 ppb) as the proportion
of subjects on ICS decreased (79%, 56%, 18%), respec-
tively. Type IV asthmatics do not follow this trend (79%
and 8.5 ppb, respectively). This observation is likely due
to the peripheral (small airway/alveolar) nature of the
inflammation which is not targeted by ICS.
In contrast, several different groups have reported clin-
ically relevant observations regarding CANO and asthma
control [5,6,31-33]. For example, increased levels of
CANO have been reported in asthmatics with nocturnal
symptoms [31], asthmatics with poor control (based on
bronchodilator use) [5] or refractory to ICS treatment
[32], as well as a predictor of asthma exacerbation [33].
These observations are consistent with our results of
poor control in children with elevated CANO (Types III
and IV comprising 26% of our population). The associa-
tion between poor asthma control and elevated CANO is
likely due to the presence of inflammation in the distal
lung which can contribute to airflow limitation [2-4].
However, our data, as well as data in the literature, also
demonstrate that that CANO is much less dependent on
confounding influences of ICS therapy and atopy com-
pared to J'awNO or FENO,50. Paraskakis et. al [5] studied a
group of more severe steroid-treated asthmatic children,
and reported that CANO was elevated in the children with
poorly controlled asthma, but not in atopic non-asth-
matic controls. Although our patient population repre-
sented relatively mild asthmatic children, we observed
that the rate of atopy and ICS therapy differed amongst
the eNO categories, but neither was related to asthmaPuckett et al. Respiratory Research 2010, 11:47
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control (e.g., rate of atopy was highest in the well-con-
trolled Type II and rate of ICS highest in poorly con-
trolled Type IV and well-controlled Type I).
Although ICS therapy does not appear to impact CANO,
nor improve control in asthmatic children with elevated
CANO, reports in the literature demonstrate that CANO
and asthma control do respond to systemic medications,
namely oral corticosteroids [32,54] and leukotriene
receptor antagonists [55]. Together, these results suggest
that proximal airway and distal airway/alveolar NO
respond differently to treatment, and thus may be of clin-
ical utility [29]. However, well-designed longitudinal
studies are necessary to determine appropriate therapeu-
tic options for achieving asthma control in children with
elevated CANO.
Study limitations
Our pediatric population was predominately Hispanic
(95%). Ethnicity may impact response to asthma medica-
tions due to genetic differences in cellular receptors [56],
and thus our results may not apply to other ethnic
groups. Approximately 10% of the asthmatic subjects did
not fit the two compartment model of NO exchange in
the lungs. However, the model was successfully applied in
all of the non-asthmatic subjects. These results are simi-
lar to the findings of Paraskakis et al. [5], and may be
related to heterogeneous ventilation and inflammation
patterns in some asthmatic subjects [57]. Finally, we
enrolled subjects independent of inhaled corticosteroid
use which allowed us to evaluate the differential effect of
Table 2: Clinical patterns of the eNO categories
Type I
Normal Nitric Oxide
Type II
Proximal Airway 
Predominant
Type III
Proximal and Distal 
Airway Predominant
Type IV
Distal Airway 
Predominant
EXHALED NITRIC OXIDE
J'awNO ( n l / s ) <  1 . 5≥  1 . 5≥  1 . 5<  1 . 5
CANO (ppb) < 2.3 < 2.3 ≥ 2.3 ≥ 2.3
FENO,50 (ppb)# ▪ ▪▪▪▪ ▪▪▪▪ ▪
THERAPY AND ATOPY
Atopy ▪▪▪ ▪▪▪▪ ▪▪▪▪ ▪▪▪
ICS treatment ▪▪▪▪ ▪▪▪ ▪ ▪▪▪▪
LUNG FUNCTION
Abnormal Spirometry ▪▪▪▪
BDR > 10% ▪▪ ▪ ▪ ▪ ▪▪
CONTROL and RISK
ACT ≤ 19 ▪ ▪ ▪▪▪▪ ▪▪▪▪
Morbidity* ▪ ▪ ▪▪ ▪▪
Proportion of subjects: ▪▪▪▪ ≥ 75%, ▪▪▪ 50-74.9%, ▪▪, 25-49.9%; ▪ <25%.
#Abnormal FENO,50 is based on the upper limit of the non-asthmatic, non-atopic controls (≥ 16 ppb).
Abnormal spirometry: FEV1 % predicted < 80% or FVC % predicted < 80% or FEV1/FVC < 80%.
Asthma control test (ACT) ≤ 19 is indicative of poor asthma control.
* Proportion of subjects with at least one event in the past 8 weeks including visits to the emergency department, severe attacks, and 
hospitalizations.Puckett et al. Respiratory Research 2010, 11:47
http://respiratory-research.com/content/11/1/47
Page 8 of 9
ICS therapy on proximal and distal eNO and the relation-
ship to asthma control.
Conclusions
In summary, we propose a novel method for non-inva-
sively categorizing asthma based on region specific NO
parameters J'awNO and CANO. We have shown that J'awNO
and CANO can be selectively elevated in asthma, permit-
ting identification of four eNO categories with distinct
clinical patterns. The categories characterized by
increased CANO (Types III and IV) have much worse (but
similar to each other) asthma control and morbidity,
despite significantly different rates of ICS therapy, atopy,
baseline spirometry and BDR. Hence, our preliminary
observations in a mobile asthma clinic setting, suggest
that categorizing asthma using proximal and distal NO
may be clinically useful, both in terms of feasibility and
management of asthma control. For example, our data
suggest that Type III and Type IV asthmatics may not
achieve good asthma control with standard ICS therapy.
Future studies must address the dynamic (i.e., longitudi-
nal) nature of the categories with regards to therapy and
disease progression, the relationship to other inflamma-
tory indices such as cells in the sputum, blood or bron-
chial biopsy, whether this categorization strategy is
relevant in maintaining asthma control and reducing
asthma morbidity, and the role of axial diffusion of NO in
active asthma. Nonetheless, these results suggest that not
one (i.e., FENO,50), but all aspects of eNO may be impor-
tant in the management of asthma, and that partitioning
eNO to determine CANOmay significantly improve the
clinical relevance of the eNO signal.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JP assisted in the design of the experiment, data collection,, and the writing
the manuscript. RT assisted in the data analysis and interpretation. S-YL per-
formed the statistical analysis, and assisted in the interpretation of the data and
the writing of specific sections of the manuscript. OG assisted in the collection
and interpretation of the data. AA assisted in the data collection through the
completion of the IRB approval, and also assisted in the interpretation of the
data. SPG and SCG conceived of the orginal concept and experimental design,
and assisted in the data interpretation and writing of the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by a grant from the National Institutes of Health (R01 
HL070645) and the Children's Hospital of Orange County.
Author Details
1Department of Biomedical Engineering, 2420 Engineering Tower, University of 
California, Irvine, Irvine, CA 92697, USA, 2Institute for Clinical Translational 
Science, 1115 Hewitt Hall, University of California, Irvine, Irvine, CA 92697, USA, 
3Children's Hospital of Orange County, 804 W. Collins, Orange, CA 92868, USA, 
4Department of Medicine, 2420 Engineering Tower, University of California, 
Irvine, Irvine, CA 92697, USA and 5Department of Chemical Engineering and 
Materials Science, 2420 Engineering Tower, University of California, Irvine, 
Irvine, CA 92697, USA
References
1. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and 
Management of Asthma-Summary Report 2007.  J Allergy Clin Immunol 
2007, 120(5 Suppl):S94-138.
2. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ: Alveolar tissue 
inflammation in asthma.  Am J Respir Crit Care Med 1996, 
154(5):1505-1510.
3. Sutherland ER, Martin RJ, Bowler RP, Zhang Y, Rex MD, Kraft M: 
Physiologic correlates of distal lung inflammation in asthma.  J Allergy 
Clin Immunol 2004, 113(6):1046-1050.
4. Payne DN, Qiu Y, Zhu J, Peachey L, Scallan M, Bush A, Jeffery PK: Airway 
inflammation in children with difficult asthma: relationships with 
airflow limitation and persistent symptoms.  Thorax 2004, 
59(10):862-869.
5. Paraskakis E, Brindicci C, Fleming L, Krol R, Kharitonov SA, Wilson NM, 
Barnes PJ, Bush A: Measurement of bronchial and alveolar nitric oxide 
production in normal children and children with asthma.  Am J Respir 
Crit Care Med 2006, 174(3):260-267.
6. Mahut B, Delacourt C, Zerah-Lancner F, De Blic J, Harf A, Delclaux C: 
Increase in alveolar nitric oxide in the presence of symptoms in 
childhood asthma.  Chest 2004, 125(3):1012-1018.
7. Wenzel SE: Asthma: defining of the persistent adult phenotypes.  Lancet 
2006, 368(9537):804-813.
8. Silkoff PE, McClean PA, Slutsky AS, Furlott HG, Hoffstein E, Wakita S, 
Chapman KR, Szalai JP, Zamel N: Marked flow-dependence of exhaled 
nitric oxide using a new technique to exclude nasal nitric oxide.  Am J 
Respir Crit Care Med 1997, 155(1):260-267.
9. Tsoukias NM, Tannous Z, Wilson AF, George SC: Single-exhalation 
profiles of NO and CO2 in humans: effect of dynamically changing flow 
rate.  J Appl Physiol 1998, 85(2):642-652.
10. ATS/ERS recommendations for standardized procedures for the online 
and offline measurement of exhaled lower respiratory nitric oxide and 
nasal nitric oxide, 2005.  Am J Respir Crit Care Med 2005, 171(8):912-930.
11. Alving K, Weitzberg E, Lundberg JM: Increased amount of nitric oxide in 
exhaled air of asthmatics.  Eur Respir J 1993, 6(9):1368-1370.
12. Kharitonov SA, Yates DH, Chung KF, Barnes PJ: Changes in the dose of 
inhaled steroid affect exhaled nitric oxide levels in asthmatic patients.  
Eur Respir J 1996, 9(2):196-201.
13. Steerenberg PA, Janssen NA, de Meer G, Fischer PH, Nierkens S, van 
Loveren H, Opperhuizen A, Brunekreef B, van Amsterdam JG: 
Relationship between exhaled NO, respiratory symptoms, lung 
function, bronchial hyperresponsiveness, and blood eosinophilia in 
school children.  Thorax 2003, 58(3):242-245.
14. Thomas PS, Gibson PG, Wang H, Shah S, Henry RL: The relationship of 
exhaled nitric oxide to airway inflammation and responsiveness in 
children.  J Asthma 2005, 42(4):291-295.
15. Sacco O, Sale R, Silvestri M, Serpero L, Sabatini F, Raynal ME, Biraghi M, 
Rossi GA: Total and allergen-specific IgE levels in serum reflect blood 
eosinophilia and fractional exhaled nitric oxide concentrations but not 
pulmonary functions in allergic asthmatic children sensitized to house 
dust mites.  Pediatr Allergy Immunol 2003, 14(6):475-481.
16. Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, 
Hodgdon K, Morgan W, Sorkness CA, Lemanske RF Jr: Relationship of 
exhaled nitric oxide to clinical and inflammatory markers of persistent 
asthma in children.  J Allergy Clin Immunol 2003, 112(5):883-892.
17. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ: Correlation 
between exhaled nitric oxide, sputum eosinophils, and methacholine 
responsiveness in patients with mild asthma.  Thorax 1998, 53(2):91-95.
18. Langley SJ, Goldthorpe S, Custovic A, Woodcock A: Relationship among 
pulmonary function, bronchial reactivity, and exhaled nitric oxide in a 
large group of asthmatic patients.  Ann Allergy Asthma Immunol 2003, 
91(4):398-404.
19. Berkman N, Avital A, Breuer R, Bardach E, Springer C, Godfrey S: Exhaled 
nitric oxide in the diagnosis of asthma: comparison with bronchial 
provocation tests.  Thorax 2005, 60(5):383-388.
20. Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, 
Koskela H, Brannan JD, Freed R, Andersson M, et al.: Predictive markers of 
Received: 10 December 2009 Accepted: 28 April 2010 
Published: 28 April 2010
This article is available from: http://respiratory-research.com/content/11/1/47 © 2010 Puckett et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Respiratory Research 2010, 11:47Puckett et al. Respiratory Research 2010, 11:47
http://respiratory-research.com/content/11/1/47
Page 9 of 9
asthma exacerbation during stepwise dose reduction of inhaled 
corticosteroids.  Am J Respir Crit Care Med 2001, 163(2):406-412.
21. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR: Use of exhaled 
nitric oxide measurements to guide treatment in chronic asthma.  N 
Engl J Med 2005, 352(21):2163-2173.
22. Zacharasiewicz A, Wilson N, Lex C, Erin EM, Li AM, Hansel T, Khan M, Bush 
A: Clinical use of noninvasive measurements of airway inflammation in 
steroid reduction in children.  Am J Respir Crit Care Med 2005, 
171(10):1077-1082.
23. Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, 
Pavord ID: The use of exhaled nitric oxide to guide asthma 
management: a randomized controlled trial.  Am J Respir Crit Care Med 
2007, 176(3):231-237.
24. Fritsch M, Uxa S, Horak F Jr, Putschoegl B, Dehlink E, Szepfalusi Z, Frischer 
T: Exhaled nitric oxide in the management of childhood asthma: A 
prospective 6-months study.  Pediatr Pulmonol 2006, 41(9):855-862.
25. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC: Titrating steroids on 
exhaled nitric oxide in children with asthma: a randomized controlled 
trial.  Am J Respir Crit Care Med 2005, 172(7):831-836.
26. Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ, 
Kattan M, Pongracic JA, Teach SJ, Bloomberg GR, et al.: Management of 
asthma based on exhaled nitric oxide in addition to guideline-based 
treatment for inner-city adolescents and young adults: a randomised 
controlled trial.  Lancet 2008, 372(9643):1065-1072.
27. Jones SL, Kittelson J, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, 
Taylor DR: The predictive value of exhaled nitric oxide measurements in 
assessing changes in asthma control.  Am J Respir Crit Care Med 2001, 
164(5):738-743.
28. Gibson PG: Using fractional exhaled nitric oxide to guide asthma 
therapy: design and methodological issues for ASthma TReatment 
ALgorithm studies.  Clin Exp Allergy 2009, 39(4):478-490.
29. Puckett JL, George SC: Partitioned exhaled nitric oxide to non-invasively 
assess asthma.  Respir Physiol Neurobiol 2008, 163(1-3):166-177.
30. Lehtimaki L, Turjanmaa V, Kankaanranta H, Saarelainen S, Hahtola P, 
Moilanen E: Increased bronchial nitric oxide production in patients 
with asthma measured with a novel method of different exhalation 
flow rates.  Ann Med 2000, 32(6):417-423.
31. Lehtimaki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E: 
Increased alveolar nitric oxide concentration in asthmatic patients 
with nocturnal symptoms.  Eur Respir J 2002, 20(4):841-845.
32. Berry M, Hargadon B, Morgan A, Shelley M, Richter J, Shaw D, Green RH, 
Brightling C, Wardlaw AJ, Pavord ID: Alveolar nitric oxide in adults with 
asthma: evidence of distal lung inflammation in refractory asthma.  Eur 
Respir J 2005, 25(6):986-991.
33. Gelb AF, Flynn Taylor C, Shinar CM, Gutierrez C, Zamel N: Role of 
spirometry and exhaled nitric oxide to predict exacerbations in treated 
asthmatics.  Chest 2006, 129(6):1492-1499.
34. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, Rosenzweig JC, 
Manjunath R: Development and cross-sectional validation of the 
Childhood Asthma Control Test.  J Allergy Clin Immunol 2007, 
119(4):817-825.
35. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, 
Pendergraft TB: Development of the asthma control test: a survey for 
assessing asthma control.  J Allergy Clin Immunol 2004, 113(1):59-65.
36. Lung function testing: selection of reference values and interpretative 
strategies. American Thoracic Society.  Am Rev Respir Dis 1991, 
144(5):1202-1218.
37. Condorelli P, Shin HW, Aledia AS, Silkoff PE, George SC: A simple 
technique to characterize proximal and peripheral nitric oxide 
exchange using constant flow exhalations and an axial diffusion 
model.  J Appl Physiol 2007, 102(1):417-425.
38. George SC, Hogman M, Permutt S, Silkoff PE: Modeling pulmonary nitric 
oxide exchange.  J Appl Physiol 2004, 96(3):831-839.
39. Tsoukias NM, George SC: A two-compartment model of pulmonary 
nitric oxide exchange dynamics.  J Appl Physiol 1998, 85(2):653-666.
40. Sepponen A, Lehtimaki L, Huhtala H, Kaila M, Kankaanranta H, Moilanen E: 
Alveolar and bronchial nitric oxide output in healthy children.  Pediatr 
Pulmonol 2008, 43(12):1242-1248.
41. Rackemann F: A clinical classification of asthma.  Am J Med Sci 1921, 
12:802-803.
42. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, 
Wardlaw AJ, Pavord ID: Asthma exacerbations and sputum eosinophil 
counts: a randomised controlled trial.  Lancet 2002, 
360(9347):1715-1721.
43. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E, 
Cartier A, Hussack P, Goldsmith CH, Laviolette M, et al.: Determining 
asthma treatment by monitoring sputum cell counts: effect on 
exacerbations.  Eur Respir J 2006, 27(3):483-494.
44. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, 
Chu HW: Evidence that severe asthma can be divided pathologically 
into two inflammatory subtypes with distinct physiologic and clinical 
characteristics.  Am J Respir Crit Care Med 1999, 160(3):1001-1008.
45. Simpson JL, Scott R, Boyle MJ, Gibson PG: Inflammatory subtypes in 
asthma: assessment and identification using induced sputum.  
Respirology 2006, 11(1):54-61.
46. Nadif R, Siroux V, Oryszczyn MP, Ravault C, Pison C, Pin I, Kauffmann F: 
Heterogeneity of asthma according to blood inflammatory patterns.  
Thorax 2009, 64(5):374-80.
47. Shin H-W, Condorelli P, George SC: Examining axial diffusion of nitric 
oxide in the lungs using heliox and breath hold.  J Appl Physiol 2006, 
100(2):623-630.
48. Shin H-W, Condorelli P, Rose-Gottron CM, Cooper DM, George SC: 
Probing the impact of axial diffusion on nitric oxide exchange 
dynamics with heliox.  J Appl Physiol 2004, 97(3):874-882.
49. Shin H-W, George SC: Impact of axial diffusion on nitric oxide exchange 
in the lungs.  J Appl Physiol 2002, 93(6):2070-2080.
50. Kerckx Y, Michils A, Van Muylem A: Airway contribution to alveolar nitric 
oxide in healthy subjects and stable asthma patients.  J Appl Physiol 
2008, 104(4):918-924.
51. Jouaville LF, Annesi-Maesano I, Nguyen LT, Bocage AS, Bedu M, Caillaud D: 
Interrelationships among asthma, atopy, rhinitis and exhaled nitric 
oxide in a population-based sample of children.  Clin Exp Allergy 2003, 
33(11):1506-1511.
52. Lehtimaki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E: 
Inhaled fluticasone decreases bronchial but not alveolar nitric oxide 
output in asthma.  Eur Respir J 2001, 18(4):635-639.
53. Moody A, Fergusson W, Wells A, Bartley J, Kolbe J: Increased nitric oxide 
production in the respiratory tract in asymptomatic pacific islanders: 
an association with skin prick reactivity to house dust mite.  J Allergy 
Clin Immunol 2000, 105(5):895-899.
54. Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM, Schein 
MJ, Epstein JD, Zamel N: Alveolar and Airway Sites of Nitric Oxide 
Inflammation in Treated Asthmatics.  Am J Respir Crit Care Med 2004, 
170:737-741.
55. Fritscher LG, Rodrigues MT, Zamel N, Chapman KR: The effect of 
montelukast on exhaled nitric oxide of alveolar and bronchial origin in 
inhaled corticosteroid-treated asthma.  Respir Med 2009, 103(2):296-300.
56. Lima JJ, Blake KV, Tantisira KG, Weiss ST: Pharmacogenetics of asthma.  
Curr Opin Pulm Med 2009, 15(1):57-62.
57. Suresh V, Shelley DA, Shin HW, George SC: Effect of heterogeneous 
ventilation and nitric oxide production on exhaled nitric oxide profiles.  
J Appl Physiol 2008, 104(6):1743-1752.
doi: 10.1186/1465-9921-11-47
Cite this article as: Puckett et al., Clinical patterns in asthma based on proxi-
mal and distal airway nitric oxide categories Respiratory Research 2010, 11:47